{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-22-000032","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2022-05-25T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.368221+00:00","generated_at":"2026-06-25T07:26:17.807018+00:00","sec_items":["8.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Neurocrine Biosciences repurchases $179.4M of convertible notes, reduces debt by ~60% over two years","bullets":["Repurchased $179.4M principal of 2.25% Convertible Senior Notes due 2024 for ~$224M cash plus stock-price-based component and accrued interest.","After repurchase, $201.8M principal remains outstanding; reduced from initial $517.5M.","CFO states debt reduction of ~60% over two years aims to minimize shareholder dilution.","Repurchases expected to close by June 14, 2022 under separate private agreements."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-22-000032","json":"https://secwatch.observer/filing/0000914475-22-000032.json","markdown":"https://secwatch.observer/filing/0000914475-22-000032.md","text":"https://secwatch.observer/filing/0000914475-22-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447522000032/0000914475-22-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447522000032/nbix-20220524.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T07:26:17.807018+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}